Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Multi-Center, Phase III Clinical Study of SHR-1701 Plus Chemotherapy Versus Placebo Plus Chemotherapy as Treatment in Patients With Previously Untreated, Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Next Previous
Trial Profile

A Randomized, Double-Blind, Multi-Center, Phase III Clinical Study of SHR-1701 Plus Chemotherapy Versus Placebo Plus Chemotherapy as Treatment in Patients With Previously Untreated, Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Retlirafusp alfa (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Suzhou Suncadia Biopharmaceuticals

Most Recent Events

  • 07 Jan 2026 According to a Jiangsu Hengrui Medicine media release, NMPA has approved Retlirafusp alfa Injection for marketing, for the first-line treatment of locally advanced unresectable, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma [PD-L1 positive (CPS >/= 1) by a fully validated test.] in combination with fluorouracil and platinum-based drugs.
  • 30 Mar 2025 Planned End Date changed from 30 Jun 2025 to 1 Oct 2025.
  • 19 Sep 2024 According to a Jiangsu Hengrui Medicine media release, Suzhou Shengdiya Biomedical Co (a subsidiary of Jiangsu Hengrui Pharmaceuticals Co Ltd), has received an ''Acceptance Notice'' from the National Medical Products Administration (NMPA), indicating that the marketing authorization application for its Relafup-alpha injection (SHR-1701) has been accepted by the NMPA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top